Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Macrogenics (MGNX) over the last 11 years, with Q3 2025 value amounting to $1.3 million.

  • Macrogenics' Other Non-Current Liabilities rose 41472.87% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 41472.87%. This contributed to the annual value of $2.0 million for FY2024, which is 66279.07% up from last year.
  • According to the latest figures from Q3 2025, Macrogenics' Other Non-Current Liabilities is $1.3 million, which was up 41472.87% from $1.7 million recorded in Q2 2025.
  • Macrogenics' Other Non-Current Liabilities' 5-year high stood at $2.0 million during Q4 2024, with a 5-year trough of $258000.0 in Q1 2021.
  • Over the past 5 years, Macrogenics' median Other Non-Current Liabilities value was $258000.0 (recorded in 2021), while the average stood at $568526.3.
  • Per our database at Business Quant, Macrogenics' Other Non-Current Liabilities crashed by 8850.78% in 2021 and then soared by 66279.07% in 2024.
  • Macrogenics' Other Non-Current Liabilities (Quarter) stood at $258000.0 in 2021, then changed by 0.0% to $258000.0 in 2022, then changed by 0.0% to $258000.0 in 2023, then soared by 662.79% to $2.0 million in 2024, then plummeted by 32.52% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.7 million for Q2 2025, and $2.0 million during Q1 2025.